Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
JS001, a humanized IgG monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate the safety, tolerability, and clinical activity of JS001 in adv...
Saved in:
| Published in | Journal of hematology and oncology Vol. 12; no. 1; pp. 7 - 15 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
14.01.2019
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1756-8722 1756-8722 |
| DOI | 10.1186/s13045-018-0693-2 |
Cover
Loading…
| Abstract | JS001, a humanized IgG
monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate the safety, tolerability, and clinical activity of JS001 in advanced melanoma or urologic cancer patients who are refractory to standard systemic therapy.
In the dose escalation cohorts, subjects initially received a single-dose, intravenous infusion of JS001, and were followed for 28 days followed by multi-dose infusions every 2 weeks. In the dose expansion cohorts, subjects received multi-dose infusions every 2 weeks. Clinical response was evaluated after each 8-week treatment cycle according to RECIST v1.1 criteria.
Thirty-six subjects diagnosed with advanced melanoma (n = 22), urothelial cancer (UC) (n = 8), or renal cell cancer (RCC) (n = 6) were enrolled. Melanoma subjects included 14 acral and 4 mucosal subtypes. JS001 was well tolerated, and no dose-limiting toxicity was observed. By the safety data cutoff date, 100% of subjects had treatment-related adverse events (TRAE) with most adverse events being grade 1 or 2, and ≥ grade 3 TRAEs occurred in 36%. Among all 36 subjects, 1 confirmed complete response (acral melanoma), 7 confirmed partial responses (2 acral melanoma, 1 mucosal melanoma, 2 UC, and 2 RCC), and 10 stable disease were observed, for an objective response rate of 22.2% (95% CI, 10.1 to 39.2), and a disease control rate of 50.0% (95% CI, 32.9 to 67.1). Clinical responses were correlated with PD-L1 expression on tumor cells, the presence of tumor infiltrating lymphocytes (TIL), baseline tumor volume, ECOG performance status, serum LDH levels, high percentage of activated CD8+ T cells and CD3- CD16+ CD54+ NK cells in the peripheral blood as well as tumor mutational burden (TMB).
JS001 was well tolerated and demonstrated promising anti-tumor activity in UC and RCC as well as in previously underexplored acral and mucosal melanoma subtypes. Subjects with an immune-active profile in the tumor microenvironment or in peripheral blood responded favorably to JS001 treatment. The completion of the current phase I study has led to the initiation of the first prospective anti-PD-1 registration trial in Asia focusing on acral and mucosal melanoma subtypes, representative of the regional disease epidemiology.
Clinical Trial ID: NCT02836795 , registered July 19, 2016, retrospectively registered. |
|---|---|
| AbstractList | Background JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate the safety, tolerability, and clinical activity of JS001 in advanced melanoma or urologic cancer patients who are refractory to standard systemic therapy. Patients and methods In the dose escalation cohorts, subjects initially received a single-dose, intravenous infusion of JS001, and were followed for 28 days followed by multi-dose infusions every 2 weeks. In the dose expansion cohorts, subjects received multi-dose infusions every 2 weeks. Clinical response was evaluated after each 8-week treatment cycle according to RECIST v1.1 criteria. Results Thirty-six subjects diagnosed with advanced melanoma (n = 22), urothelial cancer (UC) (n = 8), or renal cell cancer (RCC) (n = 6) were enrolled. Melanoma subjects included 14 acral and 4 mucosal subtypes. JS001 was well tolerated, and no dose-limiting toxicity was observed. By the safety data cutoff date, 100% of subjects had treatment-related adverse events (TRAE) with most adverse events being grade 1 or 2, and ≥ grade 3 TRAEs occurred in 36%. Among all 36 subjects, 1 confirmed complete response (acral melanoma), 7 confirmed partial responses (2 acral melanoma, 1 mucosal melanoma, 2 UC, and 2 RCC), and 10 stable disease were observed, for an objective response rate of 22.2% (95% CI, 10.1 to 39.2), and a disease control rate of 50.0% (95% CI, 32.9 to 67.1). Clinical responses were correlated with PD-L1 expression on tumor cells, the presence of tumor infiltrating lymphocytes (TIL), baseline tumor volume, ECOG performance status, serum LDH levels, high percentage of activated CD8+ T cells and CD3− CD16+ CD54+ NK cells in the peripheral blood as well as tumor mutational burden (TMB). Conclusion JS001 was well tolerated and demonstrated promising anti-tumor activity in UC and RCC as well as in previously underexplored acral and mucosal melanoma subtypes. Subjects with an immune-active profile in the tumor microenvironment or in peripheral blood responded favorably to JS001 treatment. The completion of the current phase I study has led to the initiation of the first prospective anti-PD-1 registration trial in Asia focusing on acral and mucosal melanoma subtypes, representative of the regional disease epidemiology. Trial registration Clinical Trial ID: NCT02836795, registered July 19, 2016, retrospectively registered. JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate the safety, tolerability, and clinical activity of JS001 in advanced melanoma or urologic cancer patients who are refractory to standard systemic therapy.BACKGROUNDJS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate the safety, tolerability, and clinical activity of JS001 in advanced melanoma or urologic cancer patients who are refractory to standard systemic therapy.In the dose escalation cohorts, subjects initially received a single-dose, intravenous infusion of JS001, and were followed for 28 days followed by multi-dose infusions every 2 weeks. In the dose expansion cohorts, subjects received multi-dose infusions every 2 weeks. Clinical response was evaluated after each 8-week treatment cycle according to RECIST v1.1 criteria.PATIENTS AND METHODSIn the dose escalation cohorts, subjects initially received a single-dose, intravenous infusion of JS001, and were followed for 28 days followed by multi-dose infusions every 2 weeks. In the dose expansion cohorts, subjects received multi-dose infusions every 2 weeks. Clinical response was evaluated after each 8-week treatment cycle according to RECIST v1.1 criteria.Thirty-six subjects diagnosed with advanced melanoma (n = 22), urothelial cancer (UC) (n = 8), or renal cell cancer (RCC) (n = 6) were enrolled. Melanoma subjects included 14 acral and 4 mucosal subtypes. JS001 was well tolerated, and no dose-limiting toxicity was observed. By the safety data cutoff date, 100% of subjects had treatment-related adverse events (TRAE) with most adverse events being grade 1 or 2, and ≥ grade 3 TRAEs occurred in 36%. Among all 36 subjects, 1 confirmed complete response (acral melanoma), 7 confirmed partial responses (2 acral melanoma, 1 mucosal melanoma, 2 UC, and 2 RCC), and 10 stable disease were observed, for an objective response rate of 22.2% (95% CI, 10.1 to 39.2), and a disease control rate of 50.0% (95% CI, 32.9 to 67.1). Clinical responses were correlated with PD-L1 expression on tumor cells, the presence of tumor infiltrating lymphocytes (TIL), baseline tumor volume, ECOG performance status, serum LDH levels, high percentage of activated CD8+ T cells and CD3- CD16+ CD54+ NK cells in the peripheral blood as well as tumor mutational burden (TMB).RESULTSThirty-six subjects diagnosed with advanced melanoma (n = 22), urothelial cancer (UC) (n = 8), or renal cell cancer (RCC) (n = 6) were enrolled. Melanoma subjects included 14 acral and 4 mucosal subtypes. JS001 was well tolerated, and no dose-limiting toxicity was observed. By the safety data cutoff date, 100% of subjects had treatment-related adverse events (TRAE) with most adverse events being grade 1 or 2, and ≥ grade 3 TRAEs occurred in 36%. Among all 36 subjects, 1 confirmed complete response (acral melanoma), 7 confirmed partial responses (2 acral melanoma, 1 mucosal melanoma, 2 UC, and 2 RCC), and 10 stable disease were observed, for an objective response rate of 22.2% (95% CI, 10.1 to 39.2), and a disease control rate of 50.0% (95% CI, 32.9 to 67.1). Clinical responses were correlated with PD-L1 expression on tumor cells, the presence of tumor infiltrating lymphocytes (TIL), baseline tumor volume, ECOG performance status, serum LDH levels, high percentage of activated CD8+ T cells and CD3- CD16+ CD54+ NK cells in the peripheral blood as well as tumor mutational burden (TMB).JS001 was well tolerated and demonstrated promising anti-tumor activity in UC and RCC as well as in previously underexplored acral and mucosal melanoma subtypes. Subjects with an immune-active profile in the tumor microenvironment or in peripheral blood responded favorably to JS001 treatment. The completion of the current phase I study has led to the initiation of the first prospective anti-PD-1 registration trial in Asia focusing on acral and mucosal melanoma subtypes, representative of the regional disease epidemiology.CONCLUSIONJS001 was well tolerated and demonstrated promising anti-tumor activity in UC and RCC as well as in previously underexplored acral and mucosal melanoma subtypes. Subjects with an immune-active profile in the tumor microenvironment or in peripheral blood responded favorably to JS001 treatment. The completion of the current phase I study has led to the initiation of the first prospective anti-PD-1 registration trial in Asia focusing on acral and mucosal melanoma subtypes, representative of the regional disease epidemiology.Clinical Trial ID: NCT02836795 , registered July 19, 2016, retrospectively registered.TRIAL REGISTRATIONClinical Trial ID: NCT02836795 , registered July 19, 2016, retrospectively registered. JS001, a humanized IgG monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate the safety, tolerability, and clinical activity of JS001 in advanced melanoma or urologic cancer patients who are refractory to standard systemic therapy. In the dose escalation cohorts, subjects initially received a single-dose, intravenous infusion of JS001, and were followed for 28 days followed by multi-dose infusions every 2 weeks. In the dose expansion cohorts, subjects received multi-dose infusions every 2 weeks. Clinical response was evaluated after each 8-week treatment cycle according to RECIST v1.1 criteria. Thirty-six subjects diagnosed with advanced melanoma (n = 22), urothelial cancer (UC) (n = 8), or renal cell cancer (RCC) (n = 6) were enrolled. Melanoma subjects included 14 acral and 4 mucosal subtypes. JS001 was well tolerated, and no dose-limiting toxicity was observed. By the safety data cutoff date, 100% of subjects had treatment-related adverse events (TRAE) with most adverse events being grade 1 or 2, and ≥ grade 3 TRAEs occurred in 36%. Among all 36 subjects, 1 confirmed complete response (acral melanoma), 7 confirmed partial responses (2 acral melanoma, 1 mucosal melanoma, 2 UC, and 2 RCC), and 10 stable disease were observed, for an objective response rate of 22.2% (95% CI, 10.1 to 39.2), and a disease control rate of 50.0% (95% CI, 32.9 to 67.1). Clinical responses were correlated with PD-L1 expression on tumor cells, the presence of tumor infiltrating lymphocytes (TIL), baseline tumor volume, ECOG performance status, serum LDH levels, high percentage of activated CD8+ T cells and CD3- CD16+ CD54+ NK cells in the peripheral blood as well as tumor mutational burden (TMB). JS001 was well tolerated and demonstrated promising anti-tumor activity in UC and RCC as well as in previously underexplored acral and mucosal melanoma subtypes. Subjects with an immune-active profile in the tumor microenvironment or in peripheral blood responded favorably to JS001 treatment. The completion of the current phase I study has led to the initiation of the first prospective anti-PD-1 registration trial in Asia focusing on acral and mucosal melanoma subtypes, representative of the regional disease epidemiology. Clinical Trial ID: NCT02836795 , registered July 19, 2016, retrospectively registered. Abstract Background JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate the safety, tolerability, and clinical activity of JS001 in advanced melanoma or urologic cancer patients who are refractory to standard systemic therapy. Patients and methods In the dose escalation cohorts, subjects initially received a single-dose, intravenous infusion of JS001, and were followed for 28 days followed by multi-dose infusions every 2 weeks. In the dose expansion cohorts, subjects received multi-dose infusions every 2 weeks. Clinical response was evaluated after each 8-week treatment cycle according to RECIST v1.1 criteria. Results Thirty-six subjects diagnosed with advanced melanoma (n = 22), urothelial cancer (UC) (n = 8), or renal cell cancer (RCC) (n = 6) were enrolled. Melanoma subjects included 14 acral and 4 mucosal subtypes. JS001 was well tolerated, and no dose-limiting toxicity was observed. By the safety data cutoff date, 100% of subjects had treatment-related adverse events (TRAE) with most adverse events being grade 1 or 2, and ≥ grade 3 TRAEs occurred in 36%. Among all 36 subjects, 1 confirmed complete response (acral melanoma), 7 confirmed partial responses (2 acral melanoma, 1 mucosal melanoma, 2 UC, and 2 RCC), and 10 stable disease were observed, for an objective response rate of 22.2% (95% CI, 10.1 to 39.2), and a disease control rate of 50.0% (95% CI, 32.9 to 67.1). Clinical responses were correlated with PD-L1 expression on tumor cells, the presence of tumor infiltrating lymphocytes (TIL), baseline tumor volume, ECOG performance status, serum LDH levels, high percentage of activated CD8+ T cells and CD3− CD16+ CD54+ NK cells in the peripheral blood as well as tumor mutational burden (TMB). Conclusion JS001 was well tolerated and demonstrated promising anti-tumor activity in UC and RCC as well as in previously underexplored acral and mucosal melanoma subtypes. Subjects with an immune-active profile in the tumor microenvironment or in peripheral blood responded favorably to JS001 treatment. The completion of the current phase I study has led to the initiation of the first prospective anti-PD-1 registration trial in Asia focusing on acral and mucosal melanoma subtypes, representative of the regional disease epidemiology. Trial registration Clinical Trial ID: NCT02836795, registered July 19, 2016, retrospectively registered. |
| ArticleNumber | 7 |
| Audience | Academic |
| Author | Cui, Chuanliang Zhou, Li Song, Haifeng Hu, Jinwei Yao, Sheng Yu, Jiayi Wang, Xuan Feng, Hui Li, Siming Si, Lu Kong, Yan Tang, Bixia Lian, Bin Dai, Jie Chi, Zhihong Yan, Xieqiao Bai, Xue Wang, Kai Dong, Lihou Guo, Jun Mao, Lili Wu, Hai Sheng, Xinan |
| Author_xml | – sequence: 1 givenname: Bixia surname: Tang fullname: Tang, Bixia – sequence: 2 givenname: Xieqiao surname: Yan fullname: Yan, Xieqiao – sequence: 3 givenname: Xinan surname: Sheng fullname: Sheng, Xinan – sequence: 4 givenname: Lu surname: Si fullname: Si, Lu – sequence: 5 givenname: Chuanliang surname: Cui fullname: Cui, Chuanliang – sequence: 6 givenname: Yan surname: Kong fullname: Kong, Yan – sequence: 7 givenname: Lili surname: Mao fullname: Mao, Lili – sequence: 8 givenname: Bin surname: Lian fullname: Lian, Bin – sequence: 9 givenname: Xue surname: Bai fullname: Bai, Xue – sequence: 10 givenname: Xuan surname: Wang fullname: Wang, Xuan – sequence: 11 givenname: Siming surname: Li fullname: Li, Siming – sequence: 12 givenname: Li surname: Zhou fullname: Zhou, Li – sequence: 13 givenname: Jiayi surname: Yu fullname: Yu, Jiayi – sequence: 14 givenname: Jie surname: Dai fullname: Dai, Jie – sequence: 15 givenname: Kai surname: Wang fullname: Wang, Kai – sequence: 16 givenname: Jinwei surname: Hu fullname: Hu, Jinwei – sequence: 17 givenname: Lihou surname: Dong fullname: Dong, Lihou – sequence: 18 givenname: Haifeng surname: Song fullname: Song, Haifeng – sequence: 19 givenname: Hai surname: Wu fullname: Wu, Hai – sequence: 20 givenname: Hui surname: Feng fullname: Feng, Hui – sequence: 21 givenname: Sheng surname: Yao fullname: Yao, Sheng – sequence: 22 givenname: Zhihong surname: Chi fullname: Chi, Zhihong – sequence: 23 givenname: Jun orcidid: 0000-0003-1759-0986 surname: Guo fullname: Guo, Jun |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30642373$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kltr3DAQhU1JaZJtf0BfiqEQ-uJUF8uSXgohvaUEWkjexViWd7XY0laSt-TfV86m6W4oRQaJmW-OrMM5LY6cd6YoXmN0jrFo3kdMUc0qhEWFGkkr8qw4wZw1leCEHO2dj4vTGNcINVgS9KI4pqipCeX0pHA30Jt0V4LrSj1YZzUMJehktzZXf9m0yq38JVv9-Fjh-1Pru7vy2w1CuLS5123BadOVoxnA-RFKH8op-MEvrS713AvlBpI1LsWXxfMehmhePeyL4vbzp9vLr9X19y9XlxfXlWYSp4oz03Y1aYG3suOIE9MKiWrNcC1p15neCCNYp7mmxBhaNwi3VEtJG6ON0XRRXO1kOw9rtQl2hHCnPFh1X_BhqSAkqwejsj3AQda6BVJTDCAEx8Apa6UkrIWs9WGntZna0XQ6PyPAcCB62HF2pZZ-qxpKCRMkC7x7EAj-52RiUqON2gzZLeOnqAjmkjLcNDyjb5-gaz8Fl53KVCMYYQzRv9QS8gOs632-V8-i6oIJXCNRZ2xRnP-Dyqszo9U5SL3N9YOBs72BlYEhraIfpmS9i4fgm31HHq34k6oM4B2gg48xmP4RwUjNyVW75KqcXDUnV80u8Scz2iaY786_bYf_TP4Gsyfvgw |
| CitedBy_id | crossref_primary_10_1177_10781552221074622 crossref_primary_10_3389_fonc_2019_01161 crossref_primary_10_1097_MD_0000000000030239 crossref_primary_10_3389_fonc_2022_816760 crossref_primary_10_1016_j_ctarc_2021_100379 crossref_primary_10_1186_s12943_021_01489_2 crossref_primary_10_3389_fphar_2023_1079924 crossref_primary_10_1016_j_intimp_2022_109638 crossref_primary_10_1007_s00432_022_04090_2 crossref_primary_10_1067_j_cpradiol_2024_12_010 crossref_primary_10_1097_CMR_0000000000000809 crossref_primary_10_1136_bmjopen_2021_058692 crossref_primary_10_12998_wjcc_v10_i11_3478 crossref_primary_10_1007_s40265_019_01076_2 crossref_primary_10_3390_pharmaceutics14020397 crossref_primary_10_1016_j_semcancer_2019_10_017 crossref_primary_10_1186_s40364_020_00198_0 crossref_primary_10_1158_1078_0432_CCR_19_0475 crossref_primary_10_3892_ol_2022_13550 crossref_primary_10_1038_s41392_023_01317_7 crossref_primary_10_1002_cam4_3649 crossref_primary_10_3389_fonc_2021_705294 crossref_primary_10_1007_s00280_023_04541_8 crossref_primary_10_1200_JCO_19_00210 crossref_primary_10_2217_imt_2022_0140 crossref_primary_10_3389_fimmu_2022_839901 crossref_primary_10_1002_cam4_3481 crossref_primary_10_3389_fonc_2021_621422 crossref_primary_10_1186_s13045_021_01155_6 crossref_primary_10_1007_s00262_024_03823_1 crossref_primary_10_3389_fimmu_2019_01719 crossref_primary_10_2217_imt_2022_0305 crossref_primary_10_1007_s12325_024_02981_z crossref_primary_10_1155_2019_6454989 crossref_primary_10_3389_fimmu_2021_730666 crossref_primary_10_1111_1759_7714_13541 crossref_primary_10_1038_s41598_020_72649_5 crossref_primary_10_1111_pcmr_13139 crossref_primary_10_1002_cam4_4747 crossref_primary_10_1002_INMD_20230025 crossref_primary_10_1039_D1BM00928A crossref_primary_10_1093_jjco_hyz168 crossref_primary_10_1038_s41416_023_02431_7 crossref_primary_10_1016_j_clinsp_2023_100303 crossref_primary_10_1080_19420862_2023_2236740 crossref_primary_10_1007_s10753_024_02056_9 crossref_primary_10_1080_14656566_2022_2088279 crossref_primary_10_3389_fonc_2022_796407 crossref_primary_10_1016_j_annonc_2023_09_3108 crossref_primary_10_3390_cancers15204934 crossref_primary_10_3389_fphar_2021_747416 crossref_primary_10_1111_exd_14725 crossref_primary_10_1038_s41392_021_00827_6 crossref_primary_10_1136_jitc_2024_009662 crossref_primary_10_3389_fphar_2021_714483 crossref_primary_10_1172_JCI157726 crossref_primary_10_3389_fonc_2022_1077477 crossref_primary_10_1002_cam4_4190 crossref_primary_10_20517_2394_4722_2023_139 crossref_primary_10_3389_fimmu_2023_1265202 crossref_primary_10_1001_jama_2023_20181 crossref_primary_10_3389_fonc_2023_1118301 crossref_primary_10_1007_s10238_020_00619_2 crossref_primary_10_1002_cac2_12068 crossref_primary_10_1097_MS9_0000000000001647 crossref_primary_10_1016_j_tranon_2022_101375 crossref_primary_10_3389_fimmu_2024_1363568 crossref_primary_10_1016_j_cca_2020_05_017 crossref_primary_10_1097_MD_0000000000028591 crossref_primary_10_1158_1078_0432_CCR_19_4000 crossref_primary_10_1186_s12885_023_10798_2 crossref_primary_10_1002_cti2_1172 crossref_primary_10_1001_jamanetworkopen_2020_13770 crossref_primary_10_1002_mog2_92 crossref_primary_10_1016_j_xinn_2022_100255 crossref_primary_10_1016_j_jff_2022_105350 crossref_primary_10_1097_CMR_0000000000000716 crossref_primary_10_1007_s11864_022_01007_6 crossref_primary_10_1093_oncolo_oyae211 crossref_primary_10_1634_theoncologist_2019_0405 crossref_primary_10_1186_s12935_021_01774_6 crossref_primary_10_1186_s13046_019_1394_6 crossref_primary_10_3390_cancers15205046 crossref_primary_10_4103_jcrt_jcrt_500_24 crossref_primary_10_1016_j_apsb_2020_02_004 crossref_primary_10_1016_j_eucr_2024_102742 crossref_primary_10_1634_theoncologist_2019_0498 crossref_primary_10_3389_fonc_2020_602705 crossref_primary_10_1186_s40164_021_00215_4 crossref_primary_10_1158_1078_0432_CCR_21_2210 crossref_primary_10_1016_j_bbcan_2020_188420 crossref_primary_10_3389_fonc_2022_815917 crossref_primary_10_1186_s13045_021_01095_1 crossref_primary_10_3389_fphar_2019_00726 crossref_primary_10_1007_s13555_020_00396_6 crossref_primary_10_1016_j_jpba_2021_114515 crossref_primary_10_3390_cancers12040935 crossref_primary_10_1007_s11427_024_2706_2 crossref_primary_10_1080_14796694_2024_2444862 crossref_primary_10_1186_s12935_022_02816_3 crossref_primary_10_3390_ph17040533 crossref_primary_10_1097_RLU_0000000000003520 crossref_primary_10_1186_s12885_022_09866_w crossref_primary_10_3390_ijms24076710 crossref_primary_10_1158_1078_0432_CCR_19_3922 crossref_primary_10_3389_fimmu_2021_647733 crossref_primary_10_3389_fimmu_2022_1061394 crossref_primary_10_1001_jama_2023_24735 crossref_primary_10_1016_j_intimp_2023_110973 crossref_primary_10_2147_OTT_S483753 crossref_primary_10_1016_j_jtocrr_2020_100010 crossref_primary_10_1186_s12935_023_03032_3 crossref_primary_10_1080_14712598_2020_1762561 crossref_primary_10_2147_CMAR_S260915 crossref_primary_10_36401_JIPO_24_8 crossref_primary_10_1186_s13045_020_00862_w crossref_primary_10_3390_bioengineering11111084 crossref_primary_10_3389_fonc_2021_639085 |
| Cites_doi | 10.1007/s11864-018-0560-y 10.1158/1078-0432.CCR-17-0070 10.1182/blood-2006-11-060087 10.1002/cncr.20866 10.1200/JCO.2013.53.0105 10.1016/j.ccell.2018.04.001 10.1111/pcmr.12279 10.1056/NEJMoa1305133 10.1186/1471-2407-11-85 10.1093/annonc/mdx509.004 10.1038/nm730 10.1126/scitranslmed.aad7118 10.1007/s10637-016-0373-4 10.1038/nri1806 10.1126/scitranslmed.3003689 10.1002/j.1460-2075.1992.tb05481.x 10.1097/PAI.0000000000000609 10.1158/0008-5472.CAN-03-3259 10.1038/nri2326 10.1007/s10549-016-3976-8 10.1126/science.1253735 10.1093/intimm/8.5.765 10.1084/jem.192.7.1027 10.1158/0008-5472.1089.65.3 10.1038/nature25187 10.1038/nature22071 10.1038/aps.2016.161 10.1182/blood-2008-12-195792 10.1007/s00262-006-0272-1 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2019 BioMed Central Ltd. Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s). 2019 |
| Copyright_xml | – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s). 2019 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13045-018-0693-2 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central ProQuest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1756-8722 |
| EndPage | 15 |
| ExternalDocumentID | oai_doaj_org_article_872a7a94cba2431aa8871a735b9925ba PMC6332582 A581408450 30642373 10_1186_s13045_018_0693_2 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Clinical Trial, Phase I |
| GeographicLocations | China Asia United States--US |
| GeographicLocations_xml | – name: China – name: United States--US – name: Asia |
| GrantInformation_xml | – fundername: ; grantid: 2015ZX09102017 – fundername: ; grantid: ZYLX201603 |
| GroupedDBID | --- 0R~ 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP ~8M -5E -5G -A0 -BR 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7T5 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c591t-75ebd42ba7b9d7072eb8904c51493ddefe8e85dc7c32ee34601b3c9936eceec3 |
| IEDL.DBID | DOA |
| ISSN | 1756-8722 |
| IngestDate | Wed Aug 27 01:27:14 EDT 2025 Thu Aug 21 18:32:32 EDT 2025 Fri Jul 11 02:00:05 EDT 2025 Fri Jul 25 23:41:32 EDT 2025 Tue Jun 17 21:46:29 EDT 2025 Tue Jun 10 20:29:02 EDT 2025 Thu May 22 21:18:57 EDT 2025 Thu Jan 02 22:58:49 EST 2025 Tue Jul 01 04:23:13 EDT 2025 Thu Apr 24 23:02:17 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | JS001 Urothelial cancer Monoclonal antibody Renal cell carcinoma PD-1 Melanoma |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c591t-75ebd42ba7b9d7072eb8904c51493ddefe8e85dc7c32ee34601b3c9936eceec3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-1759-0986 |
| OpenAccessLink | https://doaj.org/article/872a7a94cba2431aa8871a735b9925ba |
| PMID | 30642373 |
| PQID | 2168525503 |
| PQPubID | 54946 |
| PageCount | 15 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_872a7a94cba2431aa8871a735b9925ba pubmedcentral_primary_oai_pubmedcentral_nih_gov_6332582 proquest_miscellaneous_2179351667 proquest_journals_2168525503 gale_infotracmisc_A581408450 gale_infotracacademiconefile_A581408450 gale_healthsolutions_A581408450 pubmed_primary_30642373 crossref_primary_10_1186_s13045_018_0693_2 crossref_citationtrail_10_1186_s13045_018_0693_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-01-14 |
| PublicationDateYYYYMMDD | 2019-01-14 |
| PublicationDate_xml | – month: 01 year: 2019 text: 2019-01-14 day: 14 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of hematology and oncology |
| PublicationTitleAlternate | J Hematol Oncol |
| PublicationYear | 2019 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | C Cui (693_CR30) 2014; 3 W Zou (693_CR2) 2006; 6 W Zou (693_CR10) 2016; 8 M Ahmadzadeh (693_CR1) 2009; 114 Z Eroglu (693_CR24) 2018; 553 J Cho (693_CR19) 2016; 34 Y Agata (693_CR6) 1996; 8 693_CR21 CC McLaughlin (693_CR16) 2005; 103 GJ Freeman (693_CR8) 2000; 192 MD Hellmann (693_CR25) 2018; 33 JA Lo (693_CR15) 2014; 346 C Blank (693_CR4) 2007; 56 C Blank (693_CR11) 2004; 64 AS Navazio (693_CR28) 2016; 160 Y Kong (693_CR29) 2017; 23 JM Taube (693_CR22) 2012; 4 SL Topalian (693_CR13) 2014; 32 Z Chi (693_CR17) 2011; 11 Y Nakamura (693_CR27) 2018; 19 Y Ishida (693_CR7) 1992; 11 F Hirano (693_CR12) 2005; 65 W Zou (693_CR3) 2008; 8 J Fu (693_CR20) 2017; 38 NK Hayward (693_CR26) 2017; 545 H Dong (693_CR5) 2002; 8 F Tsushima (693_CR9) 2007; 110 O Hamid (693_CR14) 2013; 369 L Abdul Karim (693_CR23) 2018; 26 SJ Furney (693_CR18) 2014; 27 |
| References_xml | – volume: 19 start-page: 42 issue: 8 year: 2018 ident: 693_CR27 publication-title: Curr Treat Options in Oncol doi: 10.1007/s11864-018-0560-y – volume: 23 start-page: 6946 issue: 22 year: 2017 ident: 693_CR29 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-0070 – volume: 110 start-page: 180 issue: 1 year: 2007 ident: 693_CR9 publication-title: Blood doi: 10.1182/blood-2006-11-060087 – volume: 103 start-page: 1000 issue: 5 year: 2005 ident: 693_CR16 publication-title: Cancer doi: 10.1002/cncr.20866 – volume: 32 start-page: 1020 issue: 10 year: 2014 ident: 693_CR13 publication-title: J Clin Oncol doi: 10.1200/JCO.2013.53.0105 – volume: 33 start-page: 853 issue: 5 year: 2018 ident: 693_CR25 publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.04.001 – volume: 27 start-page: 835 issue: 5 year: 2014 ident: 693_CR18 publication-title: Pigment Cell Melanoma Res doi: 10.1111/pcmr.12279 – volume: 369 start-page: 134 issue: 2 year: 2013 ident: 693_CR14 publication-title: N Engl J Med doi: 10.1056/NEJMoa1305133 – volume: 11 start-page: 85 year: 2011 ident: 693_CR17 publication-title: BMC Cancer doi: 10.1186/1471-2407-11-85 – ident: 693_CR21 doi: 10.1093/annonc/mdx509.004 – volume: 3 start-page: 36 issue: 3 year: 2014 ident: 693_CR30 publication-title: Chin Clin Oncol – volume: 8 start-page: 793 issue: 8 year: 2002 ident: 693_CR5 publication-title: Nat Med doi: 10.1038/nm730 – volume: 8 start-page: 328rv4 issue: 328 year: 2016 ident: 693_CR10 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aad7118 – volume: 34 start-page: 677 issue: 6 year: 2016 ident: 693_CR19 publication-title: Investig New Drugs doi: 10.1007/s10637-016-0373-4 – volume: 6 start-page: 295 issue: 4 year: 2006 ident: 693_CR2 publication-title: Nat Rev Immunol doi: 10.1038/nri1806 – volume: 4 start-page: 127ra37 issue: 127 year: 2012 ident: 693_CR22 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3003689 – volume: 11 start-page: 3887 issue: 11 year: 1992 ident: 693_CR7 publication-title: EMBO J doi: 10.1002/j.1460-2075.1992.tb05481.x – volume: 26 start-page: e22 issue: 2 year: 2018 ident: 693_CR23 publication-title: Appl Immunohistochem Mol Morphol doi: 10.1097/PAI.0000000000000609 – volume: 64 start-page: 1140 issue: 3 year: 2004 ident: 693_CR11 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-03-3259 – volume: 8 start-page: 467 issue: 6 year: 2008 ident: 693_CR3 publication-title: Nat Rev Immunol doi: 10.1038/nri2326 – volume: 160 start-page: 181 issue: 1 year: 2016 ident: 693_CR28 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-016-3976-8 – volume: 346 start-page: 945 issue: 6212 year: 2014 ident: 693_CR15 publication-title: Science doi: 10.1126/science.1253735 – volume: 8 start-page: 765 issue: 5 year: 1996 ident: 693_CR6 publication-title: Int Immunol doi: 10.1093/intimm/8.5.765 – volume: 192 start-page: 1027 issue: 7 year: 2000 ident: 693_CR8 publication-title: J Exp Med doi: 10.1084/jem.192.7.1027 – volume: 65 start-page: 1089 issue: 3 year: 2005 ident: 693_CR12 publication-title: Cancer Res doi: 10.1158/0008-5472.1089.65.3 – volume: 553 start-page: 347 issue: 7688 year: 2018 ident: 693_CR24 publication-title: Nature doi: 10.1038/nature25187 – volume: 545 start-page: 175 issue: 7653 year: 2017 ident: 693_CR26 publication-title: Nature doi: 10.1038/nature22071 – volume: 38 start-page: 710 issue: 5 year: 2017 ident: 693_CR20 publication-title: Acta Pharmacol Sin doi: 10.1038/aps.2016.161 – volume: 114 start-page: 1537 issue: 8 year: 2009 ident: 693_CR1 publication-title: Blood doi: 10.1182/blood-2008-12-195792 – volume: 56 start-page: 739 issue: 5 year: 2007 ident: 693_CR4 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-006-0272-1 |
| SSID | ssj0061920 |
| Score | 2.5440874 |
| Snippet | JS001, a humanized IgG
monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell... Background JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and... JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell... Abstract Background JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 7 |
| SubjectTerms | Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - pharmacokinetics Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Antitumor agents Apoptosis B7-H1 Antigen - metabolism Biomarkers, Tumor - metabolism Biopsy Bladder cancer Cancer therapies Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Care and treatment CD16 antigen CD3 antigen CD8 antigen CD8-Positive T-Lymphocytes - metabolism Cell activation Complications and side effects Development and progression Disease control Dosage and administration Dose-Response Relationship, Drug Drug therapy FDA approval Female Follow-Up Studies Genetic aspects Genomes Health aspects Hematology Humans Immunoglobulin G Immunoglobulin G - administration & dosage Immunoglobulin G - adverse effects Immunoglobulin G - therapeutic use Immunotherapy Infusions, Intravenous Intravenous administration JS001 Kidney cancer Ligands Lymphocyte Activation Lymphocytes Lymphocytes T Male Melanoma Melanoma - drug therapy Melanoma - pathology Metastasis Middle Aged Monoclonal antibodies Monoclonal antibody Mucosa Mutation Oncology Patients PD-1 PD-1 protein PD-L1 protein Peripheral blood Programmed Cell Death 1 Receptor - immunology Progression-Free Survival Renal cell carcinoma Safety Safety and security measures Skin cancer Skin Neoplasms - drug therapy Skin Neoplasms - pathology T cell receptors Toxicity Tumor cells Urinary tract cancer Urologic Neoplasms - drug therapy Urologic Neoplasms - pathology Urothelial cancer |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1ba9YwNOgE8UW8W50aQRCEsDRpLn2SeRljMBE2YW8hSdP5wdbO7_Kwf-85bb66Igz68NFzAv1ycm45N0I-yKCTkiaxpFsODgpvmG-SZLotrbEabyKx3vn4hz78VR2dqbN84bbKaZVbmTgI6qaPeEe-J0ptFdi_XH6--sNwahRGV_MIjbvkHrYuQ-fLnE0OF_oG20hmafXeqsSwIDjPlnFdSyZmumho2f-_YL6hmeZZkzfU0MEj8jDbj3R_JPhjcid1T8j94xwhf0q6E9-m9TX1XUO3VY8UixdwRgTFW1cAwbNesJ_fWDn8Cn1zTY9OQJXQBcByVgC9TBe-6y897Zd0sxyFJI0IW9LcjnX1jJwefD_9esjyTAUWVV2umVEpNJUI3oS6MdyIFGzNqwh2Uy1B1LXJJquaaKIUKckK_LUgIxgxOoE6jfI52en6Lr0kFBw1jDLKwBtV6cRrnqqWtzqUsDA1TUH4dnNdzP3GcezFhRv8DqvdSA8H9HBIDycK8mlacjU227gN-QtSbELEPtnDi3557jLbOWuEN76uYvACTCXvQaaW3kgV6lqo4AvyDuntxqLTidvdvsJOYLZSvCAfBwzkd_j86HPZAmwCds6aYe7OMIFP4xy8PVMuy4mV-3eqC_J-AuNKzH3rUr9BHJChqtTaFOTFeASnPz34j9LAajM7nLNdmUO6xe-hi7iWUigrXt3-Wa_JAzARMaWOldUu2VkvN-kNmGHr8Hbgtb9p5i9z priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1ra9RAcCkVxC_i22jVFQRBWN1ks498EKmPUgonQlvot2V3s9GDa6K5O_D-vTN50WDxk3AfjptZuMx7MjszhLwSXkUpdGRRVRwSFF4yV0bBVJUabRS-icR-58VXdXyen1zIiz0yrrcaCLi-NrXDfVLn7ert71-7D6Dw7zuFN-rdOsVyHyTFhnFVCAYW-QY4Jo2bHBb5VFTAVGEsbF57bOaaugn-f9vpK45qfonyilc6ukNuD-EkPez5f5fsxfoeubkYCub3SX3qqrjZUVeXdGyCpNjLgCsjKL6EBRB8Nkv27TNLu2--KXf05BQ8C10CbLgkQC_jytXNpaNNS7dtbzNpQFhLh-ms6wfk7OjL2adjNqxYYEEW6YZpGX2ZZ95pX5Sa6yx6U_A8QBhVCLB8VTTRyDLoILIYRQ7pmxcBYhoVwbsG8ZDs100dHxMKeRsWHYXnpcxV5AWPecUr5VM4GMsyIXwkrg3D-HHcgrGyXRpilO35YYEfFvlhs4S8mY787Gdv_Av5I3JsQsSx2d0PTfvdDlpojc6cdkUevMsgcnIOTGzqtJC-KDLpXUJeIL9t34M6Kb89lDgYzOSSJ-R1h4ECCX8_uKGLAYiAg7RmmAczTFDbMAePMmVHqbdZqoyEJI-LhLycwHgSr8LVsdkiDphUmSqlE_KoF8Hpobt0Umg4rWfCOaPKHFIvf3RDxZUQmTTZk_9BxqfkFsSVeA-PpfkB2d-02_gMYreNf95p5B-b-D9L priority: 102 providerName: Scholars Portal |
| Title | Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30642373 https://www.proquest.com/docview/2168525503 https://www.proquest.com/docview/2179351667 https://pubmed.ncbi.nlm.nih.gov/PMC6332582 https://doaj.org/article/872a7a94cba2431aa8871a735b9925ba |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1da9swUGwdjL2Mfc9bl2kwGAxEZcn68GO6tZRASlk6yJuQZJkGWmfk46H_fne2E2IG28sgOMF3Aue-z7o7EfJZBp2UNIklXXNIUHjFfJUk03VujdX4JhL7naeX-uJnMZmr-cFRX1gT1o0H7gh3Yo3wxpdFDF6As_MetCL3RqpQlkKFNjQCn7dLpjobjFnBbg8zt_pkneOGIKTNlnFdSiYGXqgd1v-nST7wScN6yQMHdP6MPO0jRzrunvg5eZCaF-TxtN8bf0mama_T5p76pqK7fkeKbQt4OgTF960Ags9mwa6-s7z9FZbVPZ3MwInQBcD6egB6l259s7zzdLmi21VnHmlE2Ir2g1jXr8j1-dn1twvWn6bAoirzDTMqhaoQwZtQVoYbkYIteREhYiolGLk62WRVFU2UIiVZQKYWZITwRSdwpFG-JkfNsklvCYUUDfcXZeCVKnTiJU9FzWsdcliYqiojfEdcF_tJ43jgxa1rMw6rXccPB_xwyA8nMvJ1v-RXN2bjb8inyLE9Ik7Ibm-A3Lhebty_5CYjH5Hfrms33eu5GyucAWYLxTPypcVATYfHj75vWAAi4MysAebxABM0NA7BO5lyvYVYO5FrqyCf4zIjn_ZgXIlVb01abhEHrKfKtTYZedOJ4P5Pt5mjNLDaDIRzQJUhpFnctPPDtZRCWfHuf5DxPXkCISSW3LG8OCZHm9U2fYAwbRNG5KGZmxF5NB5PZhP4Pj27vPoxavUUrtPC_gaxnDyU |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1raxQxMNQrqF_EZ12tNoIiCEuzySbZ_SDS2pbr445iK_RbSHazetDu1nsg96P8j87s4-wi9FvhPhw3k2M3M5lH5kXIe-GUl0L70KuCgYPC8tDmXoSqiBKdKLyJxHrn0VgNv8dHF_JijfzpamEwrbKTibWgzqsM78i3eaQSCfYvE1-uf4U4NQqjq90IjYYtjv3yN7hss8-He0DfD5wf7J9_HYbtVIEwk2k0D7X0Lo-5s9qluWaae5ekLM7AckgFHPbCJz6ReaYzwb0XMXgsTmSgxpUHhZIJ-Nt7ZD0W8B4Dsr67Pz791ol-dEa60GmUqO1ZhHFI8NaTkKlUhLyn_OoZAf9rghuqsJ-meUPvHTwmj1qDle40HPaErPnyKbk_akPyz0h5Zgs_X1Jb5rQrs6RYLYFDKShe8wIIPvNJeLoXRvU3V-VLenQGuotOANamIdArf2nL6srSakoX00Yq0wxhU9r2f509J-d3sd0vyKCsSv-SUPAMMawpHMtlrDxLmY8LVigXwUKf5wFh3eaarG1wjnM2Lk3t6CTKNPQwQA-D9DA8IJ9WS66b7h63Ie8ixVaI2Ji7_qGa_jDtOTeJ5lbbNM6c5WCbWQtCPLJaSJemXDobkC2kt2mqXFfixexIbD2WxJIF5GONgQIGHj-zbZ0EbAK26uphbvYwQTBkfXDHU6YVTDPz7xgF5N0KjCsx2a701QJxQGjLSCkdkI2GBVcvXTusQsNq3WPO3q70IeXkZ922XAnBZcJf3f5YW-TB8Hx0Yk4Ox8evyUOwTzGfL4ziTTKYTxf-DdiAc_e2PXmUmDs-638B29ZuuA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+clinical+activity+with+an+anti-PD-1+antibody+JS001+in+advanced+melanoma+or+urologic+cancer+patients&rft.jtitle=Journal+of+hematology+and+oncology&rft.au=Bixia+Tang&rft.au=Xieqiao+Yan&rft.au=Xinan+Sheng&rft.au=Lu+Si&rft.date=2019-01-14&rft.pub=BMC&rft.eissn=1756-8722&rft.volume=12&rft.issue=1&rft.spage=1&rft.epage=15&rft_id=info:doi/10.1186%2Fs13045-018-0693-2&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_872a7a94cba2431aa8871a735b9925ba |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8722&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8722&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8722&client=summon |